Patients responding to anti-PD-1/PD-L1 therapy often have tumors with elevated PD-1 and PD-L1 expression and are infiltrated by CD8+ cytotoxic tumor infiltrating lymphocytes (TIL) [8, 9, 11, 12]. This evidence concerns the gene CD8A and neoplasm.